Aftercare, Musculoskeletal System and Connective Tissue with CC DRG Reimbursement

Summary & Overview

Aftercare, Musculoskeletal System and Connective Tissue with CC: Inpatient Reimbursement Overview

DRG 560 covers aftercare for musculoskeletal system and connective tissue conditions with a Complication or Comorbidity, encompassing follow-up treatments, rehabilitation, and device management that generate inpatient resource use. This Diagnosis-Related Group matters for inpatient reimbursement because it differentiates post-treatment care intensity and influences prospective Medicare payment rates based on documented complications or comorbidities.

Aftercare, Musculoskeletal System and Connective Tissue with CCDRG Aftercare, Musculoskeletal System and Connective Tissue with CCDRG 560Diagnosis-Related GroupInpatient ReimbursementMedicareOrthopedicsPhysical Medicine and RehabilitationProsthetics and Orthotics

DRG 560 Overview

DRG 560 covers inpatient admissions for aftercare related to musculoskeletal system and connective tissue conditions when a Complication or Comorbidity is present, typically involving follow-up care, wound management, rehabilitation needs, prosthetic or orthotic adjustments, or related procedures after a primary treatment or surgery. This Diagnosis-Related Group groups patients whose resource use is driven by ongoing care needs rather than initial operative management. It matters for Medicare payment because it defines average resource intensity and supports prospective payment rates for hospitals treating these post-procedural or chronic musculoskeletal care cases. Accurate clinical documentation of the Complication or Comorbidity is essential to ensure the admission is assigned to this Diagnosis-Related Group.

National Payment Rates

Across payers the observed mean payment range spans from $10K to $18K, with individual payer medians ranging roughly $10K to $20K; the widest spread between minimum and maximum observed values is Anthem (min $390 to max $39K). See the table and chart below for payer-level details and distribution. Payer labels in the charts use full names such as Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem.

Mean Rates by Payer — National — DRG 560

The CMS 2023 data represents national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows the average total payment ($12.4k), average submitted covered charges ($42.8k), average Medicare payment amount ($10.7k), and total discharges (4.7k).

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s payer means for DRG 560 range from 18K (Blue Cross Blue Shield / Anthem) up to 28K (Cigna), showing a modest spread across payers. Cigna’s mean at 28K represents the most notable deviation versus national benchmarks where Cigna’s median is lower, indicating higher regional payments in Alaska. See the table and chart below for payer-level detail and distribution percentiles.

Key Insights for Alaska

Cigna is the highest-paying payer in Alaska with a mean of 28K, while BCBS and Anthem are the lowest-paying payers with means of 18K each.
Alaska’s mean rates range from 18K to 28K across payers, with Cigna notably above the national mean band for its payer by roughly 10K compared with the national median for Cigna (17K).

Clinical Trials

Studies evaluating rehabilitation intensity and modality after hospital admission for musculoskeletal aftercare with complications (CC), such as randomized or pragmatic trials comparing early intensive inpatient physical therapy versus standard therapy for patients with postoperative complications or complex connective tissue disorders. These trials focus on patients admitted for sequelae of prior musculoskeletal surgery, fractures with delayed healing, or flare/complication of connective tissue disease who have a CC that prolongs recovery; investigators measure functional recovery, readmission, and length of stay. Results are highly relevant to providers planning individualized inpatient care pathways and to payers assessing which rehabilitation approaches reduce costly prolonged stays and downstream utilization.
Comparative effectiveness research on wound, infection, and pain management strategies in aftercare populations with comorbidities (for example, studies comparing antibiotic stewardship protocols, negative-pressure wound therapy versus standard dressings, or multimodal pain control algorithms). These observational cohorts or cluster-randomized designs enroll medically complex patients receiving aftercare for surgical sites or chronic musculoskeletal wounds with CCs (such as diabetes or immunosuppression) to determine which approaches lower complication rates and rehospitalization. Findings inform clinicians on best practices to prevent recurrent interventions and help payers identify interventions that safely reduce complications and total episode cost.
Longitudinal outcomes and care-coordination trials assessing post-discharge management and readmission prevention for patients with musculoskeletal aftercare needs and CCs, including studies of transitional care models, tele-rehabilitation, or case-management interventions. These trials target patients at high risk for readmission due to comorbid conditions, mobility limitations, or social determinants impacting recovery, measuring 30- and 90-day readmissions, functional status, and total cost of care. Evidence from these studies guides hospitals and payers on effective discharge planning, resource allocation, and bundled-payment strategies to improve outcomes and limit avoidable utilization.

Combined Anterior and Posterior Cervical Spinal Fusion without MCC: Inpatient Reimbursement Overview

502-SOFT-TISSUE-PROCEDURES-WITHOUT-CC-MCC

Soft Tissue Procedures without CC/MCC: Inpatient Reimbursement Overview

556-SIGNS-AND-SYMPTOMS-OF-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITHOUT-MCC

Signs and Symptoms of Musculoskeletal System and Connective Tissue without MCC: Inpatient Reimbursement Overview

504-FOOT-PROCEDURES-WITH-CC

Foot Procedures with CC: Inpatient Reimbursement Overview

451-SINGLE-LEVEL-SPINAL-FUSION-EXCEPT-CERVICAL-WITHOUT-MCC

Single Level Spinal Fusion Except Cervical without MCC: Inpatient Reimbursement Overview

557-TENDONITIS-MYOSITIS-AND-BURSITIS-WITH-MCC

Tendonitis, Myositis and Bursitis with MCC: Inpatient Reimbursement Overview

507-MAJOR-SHOULDER-OR-ELBOW-JOINT-PROCEDURES-WITH-CC-MCC

Major Shoulder or Elbow Joint Procedures with CC/MCC: Inpatient Reimbursement Overview

563-FRACTURE-SPRAIN-STRAIN-AND-DISLOCATION-EXCEPT-FEMUR-HIP-PELVIS-AND-THIGH-WITHOUT-MCC

Fracture, Sprain, Strain and Dislocation Except Femur, Hip, Pelvis and Thigh without MCC: Inpatient Reimbursement Overview

559-AFTERCARE-MUSCULOSKELETAL-SYSTEM-AND-CONNECTIVE-TISSUE-WITH-MCC

Aftercare, Musculoskeletal System and Connective Tissue with MCC: Inpatient Reimbursement Overview

511-SHOULDER-ELBOW-OR-FOREARM-PROCEDURES-EXCEPT-MAJOR-JOINT-PROCEDURES-WITH-CC

Shoulder, Elbow or Forearm Procedures, Except Major Joint Procedures with CC: Inpatient Reimbursement Overview

Showing 1–10 of 104

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

OpenPayer

Summary & Overview

Aftercare, Musculoskeletal System and Connective Tissue with CC: Inpatient Reimbursement Overview

DRG 560 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes